Onconetix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Proclarix Diagnostic Revenue Quarterly21.5KTarget: Substantial commercial scale-up in the EU and US
Cash and Cash Equivalents Quarterly3.7MTarget: Sufficient working capital to resolve going concern uncertainty
Common Shares Outstanding Quarterly11.5MTarget: Stabilization of capital structure post-preferred conversions
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price falling below $1.00 for 30 consecutive business daysAction: Monitor bid price post the 1-for-10 reverse split executed on May 21, 2026; evaluate further corporate actions if compliance is threatened.
- Realbotix Share Exchange Agreement ClosingTrigger: Satisfaction of closing conditions including minimum Net Cash and equity line accessAction: Track progress of the pending transaction which could transfer 75% to 90% of fully diluted equity to Realbotix's owner.
- Going Concern StatusTrigger: Depletion of the $3.7M cash reserve without securing committed financingAction: Evaluate alternative financing options, equity line of credit (ELOC) draws, or strategic partnerships to sustain operations.
Research as of 20 Jun 2026